Workflow
SXT Pharmaceuticals(SXTC)
icon
Search documents
苏轩堂上涨2.79%,报1.583美元/股,总市值1.84亿美元
Jin Rong Jie· 2025-07-30 14:06
Group 1 - The stock price of Su Xuan Tang (SXTC) increased by 2.79% on July 30, reaching $1.583 per share, with a total market capitalization of $18.4 million [1] - As of September 30, 2024, Su Xuan Tang reported total revenue of $829,500, a year-on-year decrease of 11.72%, while the net profit attributable to the parent company was -$802,600, reflecting a year-on-year increase of 91.72% [1] - Su Xuan Tang Pharmaceutical Co., Ltd. is an innovative Chinese medicine company focused on the research, production, and sales of traditional Chinese medicine pieces, particularly modern Chinese medicine pieces [1]
苏轩堂上涨2.88%,报1.605美元/股,总市值1.86亿美元
Jin Rong Jie· 2025-07-29 14:02
Group 1 - The core viewpoint of the article highlights the financial performance and market position of Su Xuan Tang (SXTC), a Chinese pharmaceutical company specializing in traditional Chinese medicine [1] - As of July 29, SXTC's stock opened at $1.605 per share, reflecting a 2.88% increase, with a total market capitalization of $18.6 million [1] - Financial data indicates that for the period ending September 30, 2024, SXTC reported total revenue of $829,500, representing a year-on-year decrease of 11.72% [1] - The company experienced a net loss attributable to shareholders of $802,600, which is a significant improvement with a year-on-year increase of 91.72% [1] Group 2 - Su Xuan Tang is identified as an innovative pharmaceutical company focused on the research, production, and sales of traditional Chinese medicine pieces, particularly modern oral and infusion forms [1] - Traditional Chinese medicine pieces have been widely used in China for thousands of years, indicating a long-standing cultural and medicinal significance [1]
China SXT Pharmaceuticals Has Regained Compliance with Nasdaq’s Minimum Bid Price Deficiency
Globenewswire· 2025-03-17 12:30
Core Viewpoint - China SXT Pharmaceuticals, Inc. has regained compliance with Nasdaq's Minimum Bid Price Requirement after a share consolidation, closing the matter with Nasdaq [1][4]. Group 1: Compliance Notification - The company received a Compliance Notice from Nasdaq on March 13, 2025, confirming it has met the Minimum Bid Price Requirement [1][4]. - Previously, on October 3, 2024, the company was notified of its failure to maintain a minimum bid price of US$1.00 per share for 30 consecutive business days [2]. Group 2: Share Consolidation - To address the Minimum Bid Price deficiency, the company executed a share consolidation on February 25, 2025, consolidating every eight ordinary shares into one [3]. - Following the consolidation, the company achieved a closing bid price of at least US$1.00 per share for 10 consecutive business days from February 25, 2025, to March 12, 2025 [4]. Group 3: Company Overview - China SXT Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Taizhou City, Jiangsu Province, China, focusing on Traditional Chinese Medicine Pieces [5].
China SXT Pharmaceuticals Has Regained Compliance with Nasdaq's Minimum Bid Price Deficiency
Newsfilter· 2025-03-17 12:30
Core Viewpoint - China SXT Pharmaceuticals, Inc. has regained compliance with Nasdaq's Minimum Bid Price Requirement after a share consolidation and has closed the matter with Nasdaq [1][4]. Group 1: Compliance Notification - The company received a Compliance Notice from Nasdaq on March 13, 2025, confirming it has met the Minimum Bid Price Requirement [1]. - Previously, on October 3, 2024, the company was notified of its failure to maintain a minimum bid price of US$1.00 per share for 30 consecutive business days [2]. - The company was given until April 1, 2025, to regain compliance under Nasdaq Listing Rules [2]. Group 2: Share Consolidation - To address the Minimum Bid Price deficiency, the company executed a share consolidation on February 25, 2025, consolidating every eight ordinary shares into one [3]. - Following the consolidation, the company achieved a closing bid price of at least US$1.00 per share for 10 consecutive business days from February 25, 2025, to March 12, 2025 [4]. Group 3: Company Overview - China SXT Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Taizhou City, Jiangsu Province, China [5]. - The company specializes in the research, development, manufacturing, marketing, and sales of Traditional Chinese Medicine Pieces (TCMPs) and TCM Homologous Supplements (TCMHS) [5].
China SXT Pharmaceuticals, Inc. Announces Share Consolidation
Globenewswire· 2025-02-21 17:35
Core Viewpoint - China SXT Pharmaceutics, Inc. will implement a share consolidation at a ratio of 1-for-8 effective February 25, 2025, to comply with Nasdaq's minimum bid price requirement of $1.00 per share [1][2]. Company Actions - The Board of Directors approved the share consolidation to regain compliance with Nasdaq's minimum bid price requirement, which necessitates a closing bid price of $1.00 or more for at least ten consecutive trading days by April 1, 2025 [2]. - Following the share consolidation, every eight shares will be consolidated into one ordinary share, with no fractional shares issued; any fractional shares will be rounded up to one ordinary share [3]. Shareholder Impact - Shareholders holding shares through banks, brokers, or other nominees will have their shares automatically adjusted to reflect the consolidation [4]. - Beneficial holders are advised to contact their bank, broker, or nominee for further information regarding the share consolidation [4]. Company Overview - China SXT Pharmaceuticals, Inc. is an innovative pharmaceutical company established in 2005, focusing on the research, development, manufacturing, marketing, and sales of Traditional Chinese Medicine Pieces [5].
SXT Pharmaceuticals(SXTC) - 2024 Q4 - Annual Report
2024-08-13 20:15
Financial Performance - For the fiscal year ended March 31, 2024, total revenue decreased by 2% to $1,928,497 compared to $1,971,679 in the previous fiscal year[180]. - The net loss for the fiscal year ended March 31, 2024, decreased by 48% to $3,098,532 from $5,934,772 in the previous fiscal year[180]. - Total revenues for the year ended March 31, 2024, were $1,928,497, a decrease of $43,182 or 2% compared to $1,971,679 for the year ended March 31, 2023[303]. - Gross profit increased by $127,700 or 30% to $553,971 for the year ended March 31, 2024, with a gross margin of 28.7% compared to 21.6% for the previous year[313]. - Total operating expenses decreased by $2,964,592 or 49% to $3,069,188 for the year ended March 31, 2024, primarily due to a significant reduction in general and administrative expenses[303]. - General and administrative expenses decreased by $3,010,706 or 53% to $2,635,622, mainly due to reduced payroll expenses and a 90% decrease in credit loss provisions[316]. - Loss from operations improved by $3,092,292 or 55% to $2,515,217 for the year ended March 31, 2024[303]. - The company generated $13,150 in revenue from a new health beverage product, contributing 1% to total revenue for the year ended March 31, 2024[311]. - The company’s total comprehensive loss for the year ended March 31, 2024, was $3,926,756, compared to $7,088,485 for the year ended March 31, 2023[344]. - The company experienced a continuous decline in revenue for the years ended March 31, 2024, 2023, and 2022, raising substantial doubt about its ability to continue as a going concern[364]. Product Development and R&D - Advanced TCMP products accounted for 49.1% of total revenue for the fiscal year ended March 31, 2024, up from 33.3% in the fiscal year ended March 31, 2023[179]. - The company has developed and marketed 11 Advanced TCMP products, 5 Fine TCMP products, and 200 Regular TCMP products[179]. - The company has decided to discontinue cooperation with major clients in the sales of Fine TCMP and will not develop or sell Fine TCMP products in the future[206]. - The company has a product portfolio of 11 Advanced TCMP products, 5 Fine TCMP products, 200 Regular TCMP products, and 200 raw medicinal materials[207]. - The R&D team has submitted 8 patent applications and 4 invention patent applications, all under substantive examination, focusing on preparation process patents[216]. - The company’s R&D strategy aims to revolutionize TCMP production using advanced technology, including e-beam processing which improved bioavailability by 15%[218][219]. - The company has established a strong R&D team of 13 researchers, focusing on innovative TCMP products that simplify administration for customers[249]. - The company has successfully commercialized multiple modernized TCMPs without the need for additional regulatory approvals[249]. Market and Customer Base - The customer base includes 57 pharmaceutical companies, 14 chain pharmacies, and 16 hospitals across five provinces in China[182]. - As of March 31, 2024, the company’s end-customer base includes 57 pharmaceutical companies, 14 chain pharmacies, and 16 hospitals across 5 provinces[214]. - The company currently contracts with over 102 distributors in the PRC and plans to expand its distribution network to increase market penetration[254]. - The company operates 4 sales offices covering 12 major provinces in China, with over 68 sales representatives managing distributor relationships[215]. Financial Structure and Compliance - The company operates under a VIE structure, consolidating the financial results of Taizhou Suxuantang in accordance with U.S. GAAP[176]. - The company has not distributed any earnings or settled amounts owed under the VIE Agreements as of the date of the annual report[191]. - The company is subject to a 10% withholding tax on dividends paid by WFOE to SXT HK, which may be reduced to 5% under certain conditions[199]. - The company has conducted foreign exchange registration under existing PRC regulations, allowing its PRC subsidiary to legally distribute earnings[201]. - The company has established contractual arrangements with Taizhou Suxuantang to consolidate financial results under U.S. GAAP due to PRC legal restrictions on foreign ownership[282]. Production and Manufacturing - The company reconstructed an 850-square-meter facility in December 2018 for TCMHS production and received a Food Manufacturing Certificate[222]. - The company has extended its production facility for lyophilization processing, enhancing its capability to produce temperature-sensitive TCMP products[222]. - The company operates GMP-certified facilities totaling approximately 1,200 square meters for Regular TCMP production and 450 square meters for Fine TCMP production[294]. - The company holds a Pharmaceutical Manufacturing Permit from the NMPA, valid until December 17, 2025[239]. - The company is GMP certified, ensuring compliance with strict quality control and assurance standards in pharmaceutical manufacturing[236]. Intellectual Property - The company holds 28 utility model and invention patents, with a validity period of 20 years from the application date[225]. - The company has submitted five additional invention patent applications recently, enhancing its intellectual property portfolio[227]. - There are currently four invention patent applications under substantive examination at the State Intellectual Property Office of PRC[181]. Strategic Goals and Future Plans - The company plans to enhance collaboration with universities and research institutes for joint R&D projects related to TCMP processing methods and quality standards[181]. - The company intends to retain future earnings to finance business expansion and does not anticipate paying cash dividends in the foreseeable future[196]. - The company aims to promote its existing brand to increase national recognition and maintain a branded pricing strategy through marketing efforts[252]. - The company is focused on developing and introducing additional Advanced TCMP products to strengthen its existing product portfolio[253]. Challenges and Risks - The company competes with established pharmaceutical companies in the TCMP market, which have greater resources and market presence[242]. - The management team has extensive experience in the pharmaceutical industry, with most members having over 10 years of relevant experience[250]. - The company experienced a significant increase in cash outflow from operating activities, with net cash used amounting to $1,928,053 for the year ended March 31, 2024, compared to $80,757 for the year ended March 31, 2023[352].
SXT Pharmaceuticals(SXTC) - 2023 Q4 - Annual Report
2023-07-31 20:15
Financial Performance - For the fiscal year ended March 31, 2023, net revenues decreased by 24% to $1,971,679 from $2,602,281 in the previous fiscal year[175]. - The net loss for the fiscal year ended March 31, 2023, increased by 3% to $5,934,772 compared to a net loss of $5,736,095 in the prior year[175]. - Total revenues for the year ended March 31, 2023, were $1,971,679, a decrease of $630,602 or 24% compared to $2,602,281 for the year ended March 31, 2022[298]. - Gross profit for the year ended March 31, 2023, was $426,271, down from $1,251,643 in the previous year, representing a decline of 66%[298]. - Loss from operations increased to $5,607,509 for the year ended March 31, 2023, compared to $5,189,673 for the year ended March 31, 2022, an increase of 8%[298]. - Interest expense net rose significantly to $476,776 in 2023 from $36,695 in 2022, marking a 1,199% increase[298]. - The accumulated deficit as of March 31, 2023, was $21,613,133, up from $15,688,278 as of March 31, 2022[344]. - The company has raised substantial doubt about its ability to continue as a going concern due to ongoing losses and declining revenues[359]. Revenue Breakdown - Advanced TCMP products accounted for 33.3% of total revenue for the fiscal year ended March 31, 2023, down from 44.7% in the previous year[174]. - Revenue from Advanced TCMP decreased by $506,180, or 44%, accounting for 33% of total revenue for the year ended March 31, 2023[302]. - Revenue from Fine TCMP decreased by $284,976, or 71%, representing 6% of total revenue for the year ended March 31, 2023[303]. - Revenue from Regular TCMP decreased by $95,912, or 12%, accounting for 35% of total revenue for the year ended March 31, 2023[304]. - Revenue from raw medicinal materials was $502,425, representing 25% of total revenue for the year ended March 31, 2023[306]. Operational Developments - The company has developed and introduced a total of 17 Advanced TCMP products, 5 Fine TCMP products, and 87 Regular TCMP products as of the date of the annual report[174]. - The company plans to enhance cooperation with universities and research institutes for joint R&D projects related to TCMP processing methods and quality standards[176]. - The company has established a production facility for lyophilization processing, enhancing the quality and shelf life of its products[219]. - The company has a well-functioning production and sales network with 5 major suppliers in key TCM provinces[210]. - The company has been expanding its production base since October 2017, covering a total land area of 33,300 square meters to meet growing demand for TCMPs[288]. Research and Development - The R&D team has submitted 8 patent applications and 4 invention patent applications, all under substantive examination, focusing on preparation process patents[213]. - The company has achieved a 15% increase in bioactive compound extraction efficiency through e-beam processing compared to regular extraction methods[216]. - The research and development team consists of 15 dedicated researchers, focusing on innovative TCMP products that simplify administration for customers[244]. - The company intends to introduce new Advanced TCMP products steadily to strengthen its market leadership position in Directly-Oral and After-Soaking-Oral TCMPs[248]. Regulatory Compliance - The company’s operations are subject to PRC laws and regulations, which may pose risks related to foreign ownership and regulatory compliance[172]. - The company has obtained all necessary business licenses from the State Administration for Market Regulation for its operations[178]. - The VIE entity has obtained the required licenses and permits for pharmaceutical manufacturing, but compliance with GMP standards is critical for ongoing operations[179]. - The company complies with China's Environmental Protection Law and has not faced any penalties for non-compliance in the past[225]. - The production of Traditional Chinese Medicine Products (TCMP) must comply with the "Pharmaceutical Administration Law of PRC (2019 Revision)" and GMP standards[257]. Employee and Management Information - As of March 31, 2023, the company had a total of 78 full-time employees, with a focus on maintaining a qualified workforce for manufacturing and quality control[250]. - The company has signed confidentiality agreements with all employees to protect its production design and intellectual property[222]. - Information regarding directors, executive officers, and key employees is provided, indicating a structured management team[367]. Future Outlook - The company intends to retain future earnings to finance business expansion and does not anticipate paying cash dividends in the foreseeable future[191]. - The company is seeking to raise capital through additional debt and equity financings to fund operations for the next 12 months[344]. - The company plans to expand its distribution network, currently contracting with over 102 distributors in the PRC, to increase market penetration[249].
SXT Pharmaceuticals(SXTC) - 2020 Q4 - Annual Report
2020-07-31 12:42
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended March 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________ to _____________. OR ☐ SHELL COMPANY REPORT PURSUANT TO SECTION 13 ...